Understanding, Diagnosing, and Managing Fibromyalgia

This activity is an archive of the live session held at the 2009 Fall Managed Care Forum. If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from April 10, 2010 to December 31, 2010.
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from Forest Laboratories and Pfizer, Inc.

 PLEASE CLICK HERE TO VIEW PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU:  View the presentation, answer the post test, complete the evaluation form and submit.  A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or by faxing them to Katie Eads at 804-747-5316.

Description
Effective management of FM is imperative to improve quality of life for patients suffering from the disease. Due to the ambiguity of symptoms, emerging evidence on the pathophysiology of pain, and the changing scope of pharmacological treatments, clinicians are being challenged to diagnose and provide long-term treatment for an illness of which our understanding is evolving. There continues to be inadequate training for physicians and nurses, which is why it is imperative to inform the Medical Directors, Case Managers, and other healthcare personnel about the newest advances in treatment, updated guidelines from the American College of Rheumatology, and how it will affect Managed Care.

Upon Completion of this activity, participants will be able to:

  • Examine ACR guidelines on diagnosing fibromyalgia

  • Analyze the newest treatments for fibromyalgia

  • Summarize the role of central pain augmentation in the pathophysiology of fibromyalgia

  • Interpret the impact of FM on the patient and managed care

  • Discuss therapies arising from the increased understanding of pain pathways

  • Identify difficulties in diagnosing patients with FM

     

Faculty: Stuart Silverman, MD, FACP, FACR
Clinical Professor of Medicine, Cedars-Sinai/UCLA

Disclosure:

 Research: Eli Lilly and Company; Merck; Novartis; Procter & Gamble; Roche; Wyeth Speakers Bureau: Eli Lilly and Company; Merck; Procter & Gamble; Roche
Consultant: Merck; Novartis; Procter & Gamble; Roche; Wyeth
  The NAMCP planning committee has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM.  Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA).  VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1 contact hours toward CMCN recertification requirements.
.

  

This activity is supported by educational grants from Forest Laboratories and Pfizer, Inc.